Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-03-07FDA Approved: GEMCITABINE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s generic gemcitabine under an Original Application (ANDA). This marks the approval of a generic…
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC [Phase 2]
A Phase 2 trial update evaluating camrelizumab with albumin-bound paclitaxel and platinum as neoadjuvant therapy for resectable non-small-ce…
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations. [Phase 2]
Phase 2 clinical trial updating the combination of ametinib and bevacizumab as first-line treatment for advanced non-small cell lung cancer …
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors [Phase 1, Phase 2]
A Phase I/II study investigating regorafenib in combination with avelumab in various solid tumors, spanning Phase 1 and Phase 2 cohorts.
-
CLINICAL_TRIALS trial_result · 2023-03-01Clinical Trial Update: Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients [Phase 3]
A phase 3 trial comparing nivolumab plus ipilimumab versus chemotherapy as first-line treatment in PS 2 or elderly patients with advanced no…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-01Clinical Trial Update: Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating carboplatin, pemetrexed, atezolizumab, and bevacizumab in chemotherapy- and immunotherapy-naïve patients with stage…
-
CLINICAL_TRIALS trial_result · 2023-03-01Clinical Trial Update: EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer [NA]
A completed clinical trial evaluating EBUS miniforceps biopsy specimens for PD-L1 testing in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors [Phase 1]
Phase 1 trial update on an arginase-1 peptide vaccine in patients with metastatic solid tumors, including non-small cell lung cancer and uro…
-
FDA approval · 2023-02-27FDA Approved: PEMETREXED — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for pemetrexed disodium from Sagent Pharmaceuticals, enabling continued availability of this generic…
-
CLINICAL_TRIALS trial_result · 2023-02-24Clinical Trial Update: A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 2]
Phase II study evaluating rulonilimab in combination with chemotherapy as first-line treatment for advanced or metastatic non-small cell lun…
-
CLINICAL_TRIALS trial_result · 2023-02-23Clinical Trial Update: Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy [Phase 2]
Phase 2 clinical trial update on hyperpolarized xenon gas MRI imaging for radiotherapy planning/assessment in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2023-02-22Clinical Trial Update: Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment [Phase 2]
Phase 2 trial update evaluating Adebrelimab with bevacizumab and albumin paclitaxel in non-squamous non-small cell lung cancer after first-l…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy [Phase 3]
Phase 3 trial evaluating local ablative stereotactic radiotherapy for residual hypermetabolic lesions in locally advanced or metastatic non-…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations [Phase 2]
Phase 2 clinical trial evaluating the best sequence of EGFR-TKI therapy in NSCLC with EGFR mutations; status not provided.
-
CLINICAL_TRIALS trial_result · 2023-02-15Clinical Trial Update: Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]
Phase 1/2 trial evaluating radiation and chemotherapy with ipilimumab followed by nivolumab in stage III unresectable non-small cell lung ca…
-
CLINICAL_TRIALS trial_result · 2023-02-14Clinical Trial Update: TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. [Phase 3]
Phase 3 trial evaluating TQB2450 with chemotherapy followed by anlotinib for first-line treatment of advanced squamous non-small cell lung c…
-
CLINICAL_TRIALS trial_result · 2023-02-14Clinical Trial Update: Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]
A Phase I/II clinical trial update for SY-3505 in ALK-positive advanced non-small cell lung cancer is ongoing, with status currently unknown…
-
FDA approval · 2023-02-13FDA Approved: GEFITINIB — Original Application (Ingenus Pharmaceuticals, LLC)
The FDA approved Ingenus Pharmaceuticals' original application for Gefitinib, establishing a generic version of the cancer drug.
-
CLINICAL_TRIALS trial_result · 2023-02-10Clinical Trial Update: BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]
A clinical trial investigating BR790 in combination with Anlotinib for adults with advanced non-small cell lung cancer in Phase 1/2.
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating nivolumab, cabozantinib S-malate, and ipilimumab in recurrent stage IV non-small cell lung cancer has completed wit…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer [Phase 1]
Phase 1 trial of DS-1205c with gefitinib in EGFR-mutant metastatic or unresectable non-small cell lung cancer was terminated; results posted…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC [Phase 3]
A Phase 3 trial evaluating toripalimab with chemotherapy versus placebo with chemotherapy in treatment-naive advanced non-small cell lung ca…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 study of GEN1044 (DuoBody-CD3x5T4) in malignant solid tumors has been terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing mil60 to bevacizumab in treatment-naïve non-squamous non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-27Clinical Trial Update: A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors [Phase 1]
Phase 1 study evaluating drug-drug interaction between brigatinib and midazolam in ALK+ or ROS1+ solid tumors completed with posted results …